RxDoctor Payments Data

Victoria Rothwell, MD

Gastroenterology · Charlotte, NCNPI 1316365067

Payments from drug & device makers

$22,479in general payments, 2019–2025

Across 1,282 payments — averaging $17.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$5K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$3K
  • Johnson & Johnson$2K
  • Takeda Pharmaceuticals U.S.A., Inc.$2K
  • QOL Medical, LLC$1K
  • Bristol Myers Squibb$964
  • plus $9K from 40 others

What the payments were for

  • Food & beverage$22,20699%
  • Education$2741%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$22,479 in reported general payments places this provider in the 80th percentile of 610 gastroenterology providers in North Carolina.

See all gastroenterology providers in North Carolina

Medicare billing

Part B allowed, 2024
$87,546
Medicare patients
231
Services billed
1,019

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntyvioVedolizumab13$110,889
XeljanzTofacitinib Citrate12$65,798
ZenpepLipase/Protease/Amylase22$61,415
LinzessLinaclotide57$52,184
MotegrityPrucalopride Succinate25$21,505
TrulancePlecanatide22$20,728
Mesalamine ErMesalamine11$6,739
ClenpiqSod Picosulf/Mag Ox/Citric Ac31$5,333
Dexlansoprazole DrDexlansoprazole11$4,406
Lubiprostone20$4,269
CholestyramineCholestyramine (With Sugar)37$3,580
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates51$3,402
Omeprazole200$2,926
Esomeprazole Magnesium62$2,543
Dicyclomine Hcl53$892

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Takeda Pharmaceuticals U.S.A., Inc.Entyvio, Motegrity$1,625$132,39438 claims
PfizerXeljanz$810$65,79812 claims
Aimmune Therapeutics, Inc.Zenpep$602$61,41522 claims
AbbVieLinzess$5,064$52,18457 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance$3,123$20,72822 claims
Ferring Pharmaceuticals Inc.Clenpiq$265$5,33331 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 610 gastroenterology providers in North Carolina.

Other gastroenterology in Charlotte

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →